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HIF is a heterodimeric transcription factor composed of a labile 
α subunit (HIFα) and a stable β subunit (HIFβ) (1). The human 
genome encodes 3 HIFα subunit genes (HIF1A, HIF2A, HIF3A) 
and 3 HIFB genes (1). Under normal oxygen conditions, HIFα 
subunits bind with the VHL gene product, pVHL, which acts 
as the substrate recognition component of an E3 ubiquitin 
ligase complex. pVHL, along with other members of the pVHL 
ubiquitin ligase complex, polyubiquitinates and destroys HIFα 
subunits in a proteasome-dependent manner. The binding of 
HIFα by pVHL is dependent upon the oxygen-dependent, post-
translational hydroxylation of HIF subunits on either of two 
conserved prolyl residues (1). This prolyl hydroxylation is cat-
alyzed by the oxygen-dependent EGLN (also known as PHD) 
family of prolyl hydroxylases (2). Thus, HIFα subunits are nor-
mally degraded by pVHL in the presence of oxygen but stabilized 
under conditions of hypoxia or in the setting of pVHL inactiva-
tion. HIFα subunits have a very short half-life (measured in min-
utes during normoxia) and therefore are sensitive to changes in 
protein translation, such as those mediated by the mammalian 
target of rapamycin (mTOR) (3–5).
While HIF protein stability is modulated primarily by oxygen 
levels and the pVHL status of cells, HIF mRNA levels and protein 
synthesis are regulated primarily in an oxygen-independent man-
ner. For example, activation of the PI3K and MAPK pathways via 
growth factor receptor tyrosine kinases (RTKs), tumor suppres-
sor loss, or oncogene activation have all been shown to result in 
variable increases in both HIF mRNA and protein levels (1, 6–10). 
HIF accumulation leads to the direct activation of more than 100 
target genes (1). While the majority of these genes are involved 
in the cellular and organismal adaptation to hypoxia, a substan-
tial proportion of these genes are potentially capable of promot-
ing tumor progression. For example, genes involved in angio-
genesis (VEGF, PDGF, PIGF), degradation of the extracellular 
matrix (MMPs), metastasis (LOX, CXCR4, SDF1), epithelial to 
mesenchymal transition (SNAIL, SIP, ZEB), and immortalization 
(hTERT) are known HIF target genes (1, 11).
Despite sharing similar functional domains and substantial 
sequence homology, HIF1α and HIF2α do not appear to be fully 
redundant in function. First, while knockout of either Hif1a or Hif2a 
in mice leads to embryonic lethality, both the timing and cause of 
death appear to differ. Hif1a–/– mice die in mid-gestation and exhibit 
severe blood vessel defects, whereas Hif2a–/– mice exhibit late embry-
onic or early postnatal lethality as a consequence of catecholamine 
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deficiency or lung maturation defects (12–14). Second, the func-
tional differences between HIF1α and HIF2α do not appear to be 
limited to their roles in development, as a recent report also dem-
onstrates that postnatal deletion of Hif1a or Hif2a results in differ-
ing phenotypes (15). Finally, studies from our laboratory and others 
have now demonstrated that HIF1α and HIF2α produce overlap-
ping yet distinct gene expression profiles and that certain target 
genes are uniquely regulated by either HIF1α or HIF2α (16–20).
HIF’s role in tumorigenesis is best characterized in the context of 
renal cell carcinoma (RCC), where HIF2α appears to play a special 
role (21). VHL–/– renal carcinomas demonstrate obligate expression 
of HIF2α, but not HIF1α, suggesting a selective pressure to main-
tain HIF2α expression (22, 23). An apparent switch from HIF1α to 
HIF2α expression occurs in preneoplastic lesions arising in human 
VHL+/– kidneys in association with increasing dysplasia and cellu-
lar atypia (24). Finally, in VHL–/– RCCs, HIF2α, rather than HIF1α, 
appears to be necessary and sufficient for tumor growth (25–28). 
Thus, at least in VHL-deficient RCC, HIF2α is the relevant onco-
genic HIF family member (29).
Evidence also suggests that hypoxia, HIF, and in particular HIF2α 
may play an important role in the pathogenesis and prognosis of 
lung cancer. Prior work has indicated that intratumoral hypoxia is 
clearly present, even in some early-stage lung cancers, and correlates 
with a decreased overall survival (30, 31). Furthermore, HIF1A mRNA 
is one of 3 transcripts that have been validated to stratify early-stage 
non–small cell lung cancer (NSCLC) patients into groups with differ-
ent prognoses (32). Interestingly, while multiple studies have shown 
that HIF1α is overexpressed at the protein level in a substantial pro-
portion (33%–62%) of NSCLCs, patients with elevated HIF1α protein 
levels do not have a shortened overall survival (33, 34).
HIF2α, like HIF1α, is frequently overexpressed at the protein 
level in NSCLC (50%) (33). However, overexpression of HIF2α, in 
contrast to HIF1α, correlates with decreased survival, suggesting 
that HIF2α either causes, or is a surrogate marker for, poor clinical 
outcome (33). Finally, it is notable that bevacizumab, the mono-
clonal antibody targeting VEGF (a canonical HIF target gene) and 
sunitinib, the small molecule tyrosine kinase inhibitor that targets 
VEGFR2 (among other tyrosine kinases), have shown clinical ben-
efit for patients with metastatic NSCLC (35, 36).
To evaluate the role of HIF2α in lung tumorigenesis, we gen-
erated cohorts of mice that conditionally expressed mutant 
KrasG12D with or without a conditionally expressed variant of 
stabilized HIF2α (HIF2dPA). Our data reveal that lung-specific 
expression of HIF2dPA on a background of mutant Kras leads 
to the development of lung cancers with highly pleomorphic 
histology and features of epithelial-mesenchymal transition 
(EMT), increased vascularization and blood flow, as well as ele-
vated levels of circulating endothelial cells (CECs) and circulat-
ing endothelial progenitor cells (CEPs). Furthermore, mice har-
boring HIF2dPA-expressing lung cancers exhibited an increased 
tumor burden, more invasive tumors, and a shortened median 
survival. These genetic results complement existing human 
clinical data to implicate HIF2α as a negative prognostic factor 
in human NSCLC and demonstrate that HIF2α can promote 
tumor growth in tumors other than renal cell carcinoma and 
specifically in Kras mutant lung carcinoma.
Figure 1
Mice harboring HIF2α-producing lung tumors have a shortened survival and larger tumors. (A) Kaplan-Meier survival curve of cohorts of 
LSL-Kras (n = 9) and LSL-Kras;LSL-HIF2 (n = 12) mice (P = 0.036). (B) Photomicrographs of representative lung tumors from LSL-Kras and 
LSL-Kras;LSL-HIF2 mice. Arrows indicate visible subpleural tumors. (C) Quantification of tumor area as a percentage of lung area. Error bars 
indicate 1 SEM (P = 0.031).
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Results
Expression of HIF2dPA decreases survival of mice with Kras-induced lung 
tumors. We previously generated knock-in mice that expressed a 
conditionally activatable form of HA-tagged HIF2α (HIF2dPA) 
that escapes recognition by pVHL by virtue of proline-to-alanine 
substitutions (hereafter called LSL-HIF2 for simplicity) (16). Spe-
cifically, the ROSA26 locus of these mice harbors a Lox-Stop-Lox cas-
sette interposed between the endogenous ROSA26 promoter and 
the HIF2dPA cDNA, and the levels of HIF2α expressed are rela-
tively physiologic (16). Therefore, transcription is under control of 
the ROSA26 promoter but dependent upon Cre-mediated excision 
of the floxed stop element.
Adenovirus encoding Cre recombinase (Ad-Cre) can be delivered 
to the murine lung by intranasal administration. Mice harboring 
a conditionally activatable allele of mutant KrasG12D, Lox-Stop-Lox 
KrasG12D (hereafter called LSL-Kras) develop multifocal tumors 
with a relatively long latency and low invasive potential (37–40). 
To determine the role of HIF2α in lung tumorigenesis, we inter-
crossed the LSL-HIF2 mice to LSL-Kras mice to generate cohorts 
of LSL-Kras;LSL-HIF2 and littermate control LSL-Kras mice. These 
cohorts were then treated with a low dose of intranasal Ad-Cre 
(2.5 × 106 PFU) (38). LSL-Kras mice treated with intranasal Ad-Cre 
developed multiple tumors with a moderate multiplicity and 
had a median survival of 57 weeks (Figure 1A and Table 1). 
LSL-Kras;LSL-HIF2 mice also developed lung tumors with approxi-
mately the same multiplicity (P = 0.69; Table 1) but with a short-
ened median survival of 42 weeks (P = 0.036; Figure 1A and Table 
1). Therefore, the data indicate that expression of HIF2α within 
Kras-induced lung carcinomas does not increase tumor multiplic-
ity but confers a shortened survival.
HIF2α-producing Kras-induced lung tumors are larger and result in 
an increased lung tumor burden. Gross examination of the visceral 
pleura of inflated lungs taken from 40-week-old LSL-Kras mice 
showed numerous tumors up to 3 mm in size. Age-matched 
LSL-Kras;LSL-HIF2 mice harbored significantly larger tumors, 
which occasionally reached 10 mm in diameter (P < 0.001; Figure 
1B and Table 1). These data show that expression of HIF2α pro-
motes the formation of larger tumors.
To determine whether the shortened survival of LSL-Kras;LSL-HIF2 
mice resulted from an increase in lung tumor burden, we compared 
the total tumor area in LSL-Kras and LSL-Kras;LSL-HIF2 mice. To this 
end, we quantified low-power magnifications of a random section 
chosen from the right upper (apical) lobe (RUL) of mice for tumor 
area as well as total lung area. These measurements were used to 
determine the percentage of the RUL affected by tumor. At 40 weeks, 
LSL-Kras;LSL-HIF2 mice had a statistically significantly increased 
tumor burden relative to LSL-Kras mice (P = 0.031; Figure 1C). 
Despite these differences in tumor involve-
ment, there was no significant difference in 
either proliferation, as measured by Ki67 
staining (P = 0.45; Supplemental Figure 1A; 
supplemental material available online with 
this article; doi:10.1172/JCI38443DS1), or 
apoptosis, as measured by TUNEL staining 
(P = 0.85; Supplemental Figure 1B), between 
the tumors of LSL-Kras and LSL-Kras;LSL-HIF2 
 mice. This may reflect that fact that these 
measurements were taken at a late time 
point in the growth of these tumors. Alter-
natively, it is also possible that the increased 
tumor burden found in the LSL-Kras;LSL-HIF2 mice is a reflection of 
alterations in tumor cell size, tumor edema or vascularity, or other 
increases in the non-neoplastic population of tumor-associated 
stromal cells (such as seen in Figure 2B). These data suggest that 
expression of HIF2dPA in Kras-induced lung carcinomas results in 
larger tumors and increased total lung tumor burden.
Kras-induced lung tumors expressing HIF2dPA have distinct gene expres-
sion changes. Numerous studies have used gene expression profil-
ing to assess the transcriptional effects of VHL loss or HIF overex-
pression on cell lines (17, 19, 41, 42). We had previously examined 
the gene expression changes induced by Vhl loss or expression of 
stabilized forms of HIF1α and HIF2α within hepatocytes of mice 
(16). To validate that expression of stabilized HIF2α resulted in sig-
nificant changes in gene expression, we extracted total mRNA from 
5 macrodissected tumors of both LSL-Kras and LSL-Kras;LSL-HIF2 
mice and performed gene expression analysis using high-density 
oligonucleotide arrays. The gene expression patterns of LSL-Kras 
and LSL-Kras;LSL-HIF2 tumors were then examined by unsupervised 
hierarchical gene clustering. The transcriptional effects of HIF2α 
were readily demonstrable by this approach; unsupervised analysis 
showed that the tumors clustered into two separate groups based 
on the presence or absence of HIF2dPA expression (Supplemental 
Figure 2) and were notable for the presence of several canonical HIF 
target genes such as Vegf, Tgfb1, Egln3, and Cxcl12 (Supplemental 
Figure 2). Therefore, our data indicate that expression of HIF2dPA 
within lung tumors results in activation of canonical HIF target 
genes and significant changes in gene expression.
HIF2α-producing lung tumors are poorly differentiated, with focal 
squamous differentiation, and display increased invasiveness. Histologi-
cal examination of tumors from 40-week-old LSL-Kras mice, as 
expected, showed adenomatous alveolar hyperplasia and mod-
erately to well-differentiated adenocarcinomas with bronchoal-
veolar carcinoma (BAC), acinar, and papillary features (Figure 
2A), as described by others (37, 38, 43). Lungs from age-matched 
LSL-Kras;LSL-HIF2 mice harbored two distinct subsets of tumors. 
Tumors of the first subset were reminiscent of those found in 
LSL-Kras mice. However, tumors of the second subset were poorly 
differentiated and displayed more cytologic atypia with pleomor-
phic histology (Figure 2A and Table 1) as well as increased fibrous 
stroma (Figure 2B and Table 1); occasional necrosis (Figure 2C); 
rare invasion of local structures (Table 1) such as the pleura (Fig-
ure 2D), myocardium (Figure 2E), and mediastinal adipose tissue 
(Figure 2F); or metastases to regional lymph nodes (Figure 2G).
Poorly differentiated tumors were statistically significantly more 
frequent in LSL-Kras;LSL-HIF2 mice than their LSL-Kras counter-
parts (P = 0.027; Table 1). Examination of these tumors revealed 
occasional areas consistent with squamous differentiation. These 
Table 1
Comparison of lung cancer cohorts
	 LSL-KRas	 LSL-KRas;LSL-HIF2	 P
Median survival 57 wk 42 wk 0.03
Mean tumor number (SEM) 48 (6.5) 47.3 (7.6) 0.69
Mice with tumor >3 mm 0/17 (0%) 10/18 (55%) <0.001
Mice with local invasion or metastases 0/40 (0%) 2/12 (16%) 0.05
Tumors with increased stroma 1/153 (0.65%) 25/593 (4.2%) 0.03
Poorly differentiated tumors 4/153 (2.6%) 45/593 (7.6%) 0.027
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 8   August 2009 2163
cells had abundant eosinophilic cytoplasm, more centrally placed 
nuclei with prominent nucleoli, and less apparent polarity, fea-
tures suggestive of squamous differentiation (Figure 3A). In addi-
tion, the areas that appeared morphologically squamous had high 
nuclear expression of the squamous cell marker p63 according to 
immunohistochemistry (Figure 3B), in a background of p63-nega-
tive adenocarcinoma cells (43).
The presence of squamous differentiation was interesting, as 
Kras-induced lung tumors are uniformly adenocarcinomas (37–40, 
43). Even concurrent deletion of p53 or Pten, while promoting the 
development of higher-grade tumors, does not alter their histologic 
spectrum (44, 45). In contrast, we had previously described that 
inactivation of the Lkb1 tumor suppressor gene within Kras-induced 
lung tumors results in an expanded histologic spectrum including 
adeno-, squamous, and large cell carcinomas (43). We therefore que-
ried the DNA microarray dataset generated on these Lkb1-deficient 
mouse lung tumors to see whether Hif2a gene expression correlated 
with histologic subtype. In keeping with the notion that HIF2α pro-
motes squamous differentiation, we found that Kras-induced, Lkb1-
deficient squamous cell or mixed adeno-squamous tumors had 
significantly higher levels of HIF2α gene expression relative to Kras-
induced, Lkb1-deficient adenocarcinomas (Supplemental Figure 3, 
A and B). Therefore, the data indicate that HIF2α gene expression is 
upregulated in mouse squamous cell lung carcinomas and that pro-
duction of HIF2α in Kras-induced lung tumors promotes squamous 
differentiation but not frank squamous cell carcinoma.
Kras-induced lung tumors expressing HIF2dPA have increased vascular-
ity and blood flow. We next compared the vascularity of the autoch-
thonous lung tumors by CD34 staining and quantification of 
microvessel density (MVD). Lungs from Ad-Cre–treated LSL-Kras 
and LSL-Kras;LSL-HIF2 mice were harvested, formalin fixed, and 
stained with antibodies against the endothelial cell marker CD34. 
The number of microvessels per high-power field was quantified 
by a reviewer blinded to the research protocol. As expected, the 
lung tumors from LSL-Kras;LSL-HIF2 mice displayed a significantly 
increased number of microvessels per high-power field relative to 
lung tumors from age-matched, littermate LSL-Kras control mice 
(P < 0.001; Figure 4, A and B).
Increases in MVD do not necessarily translate into augmentation 
of blood flow, in part because of alterations in vascular permeabil-
ity and heterogeneous blood flow within tumors (46). We and oth-
ers have previously shown that the vessels formed by expression of 
stabilized forms of HIF in the skin are not conspicuously hyperper-
meable (16, 47). However, these studies did not directly assess blood 
flow or the effects of HIF on tumor-associated blood vessels.
We asked whether the increase in vascular density seen by CD34 
staining of HIF2α-producing lung tumors correlated with actual 
increases in blood flow. Because ultrasound waves are disrupted by 
pulmonary air, we were not able to image the primary tumors in 
situ in the lung, and therefore single-cell suspensions of primary 
tumors from LSL-Kras and LSL-Kras;LSL-HIF2 mice were injected 
subcutaneously into the flanks of nude mice. These tumors were 
then serially imaged with ultrasound and power Doppler sonog-
raphy. Regions of blood flow were determined by power Doppler, 
while tumor volume was determined by 3D reconstruction of 
ultrasound images. The percent vascularity was determined as the 
ratio of blood flow to tumor volume. When matched for tumor 
volume, LSL-Kras;LSL-HIF2 tumors had a statistically significantly 
Figure 2
HIF2α-producing tumors are pleomorphic and invasive. (A) Representative low- and high-power photomicrographs of H&E-stained lung tumors 
of 40-week-old LSL-Kras and LSL-Kras;LSL-HIF2 mice. (B–G) H&E staining showing increased fibrous stroma (B, asterisk) as well as necrosis 
(C, asterisk) in a lung tumor from a 40-week-old LSL-Kras;LSL-HIF2 mouse. Tumors from 40-week-old LSL-Kras;LSL-HIF2 mice also showed 
features of invasiveness, such as invasion through the visceral pleura (D), myocardial invasion (E), direct invasion of mediastinal fat (F), and 
mediastinal lymph node metastases (G). Original magnification, ×100 (B, C, F, and G); ×40 (D and E). The dashed yellow line indicates the divi-
sion between normal lymph node and tumor; yellow asterisk indicates tumor.
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higher percent vascularity than LSL-Kras tumors (P = 0.028; Fig-
ure 4, C and D). Additionally, while the percent vascularity of 
LSL-Kras tumors appeared to decline as the tumors enlarged (fitted 
exponential decay curve, r2 = 0.87) the LSL-Kras;LSL-HIF2 tumors 
were more vascular at baseline, and this high percent vascularity 
persisted despite tumor growth (fitted exponential decay curve, 
r2 = 0.21) (Figure 4E). Therefore, the increased MVD seen in tumors 
expressing stabilized HIF2α appears to be paralleled by an increase 
in blood flow in tumor explants derived from these tumors.
Mice harboring HIF2α-producing lung tumors have elevated levels of CECs 
and CEPs. Increased numbers of CECs and CEPs have been detected 
in the peripheral blood of patients with solid tumors, including 
those with lung cancer (48–52). Several chemokines and cytokines 
known to be upregulated by HIF, such as VEGF and CXCL12, have 
been shown to be involved in the mobilization and homing of 
CECs and CEPs (50, 53–55). We therefore asked whether produc-
tion of stabilized HIF2α within lung tumors could stimulate the 
numbers of CECs and CEPs. To this end, we enumerated the num-
bers of CECs and CEPs by flow cytometry in the peripheral blood 
of LSL-Kras and LSL-Kras;LSL-HIF2 mice, 12 weeks after treatment 
with Ad-Cre. CECs were defined as CD45–CD117–CD31+VEGFR2+, 
while CEPs were defined as CD45dimCD117+CD31+VEGFR2+. The 
lungs from these mice grossly appeared to have approximately the 
same tumor burden. Interestingly, the number of CECs and CEPs 
present in the peripheral blood of LSL-Kras;LSL-HIF2 mice was sta-
tistically significantly increased relative to that of LSL-Kras mice 
(P = 0.027 and P = 0.014, respectively) (Figure 5, A and B). This 
increase in CEPs, which are thought to be bone marrow derived, 
suggest that expression of stabilized HIF2α within tumors pro-
motes the mobilization of CEPs in an endocrine fashion.
HIF2α-producing tumors express markers of EMT in vivo. To bet-
ter understand how HIF2α activation within Kras-induced lung 
tumors might impart the phenotypes described, we performed 
gene set enrichment analysis (GSEA) using GSEA 2.0 (http://
www.broad.mit.edu/gsea) on our dataset of mouse lung tumors. 
Specifically, an established collection of more than 100 cancer-
related, curated gene sets provided by the Molecular Signatures 
Database (MSigDB, broad.mit.edu/gsea/msigdb) as well as those 
collected from the literature (56–59) were used to interrogate the 
gene expression dataset in order to compare gene set enrichment 
in LSL-Kras and LSL-Kras;LSL-HIF2 tumors (Supplemental Table 
2). We found 14 gene signatures to be enriched in HIF2α-pro-
ducing tumors relative to their mutant Kras controls using a 
false discovery rate (FDR) calculation (P < 0.05) to account for 
multiple hypothesis testing (Supplemental Figure 4). Notably, 
a significant number of the enriched gene sets were classifiers 
for either EMT or pathways known to induce EMT, such as the 
WNT/β-catenin and TGF-β pathways (60).
HIF has been implicated in promoting EMT (1, 61–64). Given 
our GSEA results and the invasive and metastatic nature of tumors 
derived from LSL-Kras;LSL-HIF2 mice, we hypothesized that they 
may express markers associated with EMT. We first asked wheth-
er these tumors had increased expression of genes implicated in 
inducing EMT by directly querying our gene expression dataset 
of LSL-Kras and LSL-Kras;LSL-HIF2 tumors. Interestingly, tumors 
expressing HIF2dPA had increased levels of several mRNA tran-
scripts implicated causally or associated with EMT including Sip, 
Snail, Zeb1, and vimentin (all P < 0.01) (Figure 6A). In addition, 
LSL-Kras;LSL-HIF2 tumors also stained positively for vimentin by 
immunohistochemistry (Figure 6B). These data are consistent with 
the notion that HIF2α can induce a program of genes and markers 
involved in EMT in mouse lung carcinomas and suggest a possible 
reason why HIF2α-producing tumors are more invasive.
HIF2α activation and EMT gene signatures are associated in human 
lung cancer. We asked whether the association between HIF2α and 
EMT that we saw in our autochthonous murine lung tumors was 
present in human lung cancers. To that end, we first derived an 
HIF2α gene signature from our mouse lung tumors. The gene 
expression profiles of the LSL-Kras and LSL-Kras;LSL-HIF2 tumors 
were compared using 2-class unpaired significance analysis of 
microarrays (SAM). The lowest FDR allowing the selection of 
200 upregulated genes was chosen. Using an FDR of 0.71%, we 
were able to define 396 significantly upregulated and 171 signifi-
cantly downregulated genes. Human orthologs of the top 200 
upregulated genes were determined and used to define an HIF2α 
gene signature (Supplemental Table 1).
We next queried publicly available gene expression datasets of 
human lung cancer cell lines (65) or primary NSCLCs (66) for the 
presence or absence of our HIF2α gene signature as well as the 
EMT, β-catenin, and TGF-β gene signatures (67–69). To deter-
mine whether an association was present between HIF2α activa-
tion and upregulation of gene signatures of EMT, β-catenin, and 
TGF-β, Genomica software (genomica.weizmann.ac.il) was used to 
calculate HIF2α, EMT, β-catenin, and TGF-β enrichment scores 
for each tumor or cell line. The association between each of the 
Figure 3
Squamous differentiation of HIF2α-producing lung tumors. (A) An H&E-
stained lung tumor from a 40-week-old LSL-Kras;LSL-HIF2 mouse 
shows squamous features, including abundant eosinophilic cytoplasm, 
centrally placed nuclei with prominent nucleoli, and apparent loss of 
polarity (asterisk). (B) High-power photomicrograph of high nuclear 
p63 expression in a background of p63-negative adenocarcinoma as 
detected by immunohistochemistry of a LSL-Kras;LSL-HIF2 tumor. 
Original magnification, ×400.
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gene signatures was then determined by calculating a Pearson cor-
relation coefficient. Our HIF2α gene signature correlated with 
enrichment of EMT, β-catenin, and TGF-β gene signatures in both 
the lung cancer cell lines and the primary human NSCLCs (all 
P < 0.001; Figure 7, A and B). Therefore, our HIF2α gene signature 
appears to be applicable across species and is associated with EMT 
gene expression changes in human lung cancers.
Discussion
We found that production of stabilized HIF2α in Kras-induced 
lung carcinomas resulted in larger, more invasive lung tumors and 
was associated with a shortened survival of mice harboring these 
tumors. Additionally, production of stabilized HIF2α led to the 
development of tumors with a poorly differentiated and pleomor-
phic histology that expressed markers of EMT. Consistent with 
HIF’s role in promoting angiogenesis, the HIF2α-producing lung 
tumors were found to have increased vascularity, and importantly, 
these tumors, when explanted into nude mice, were found to have 
increased blood flow at all stages of tumor development. Moreover, 
we detected higher levels of CECs and CEPs in the peripheral blood 
of mice harboring HIF2α-producing lung cancers, suggesting that 
tumors that produce HIF2α can mobilize these cells from the 
tumor endothelium and bone marrow. Collectively, these results 
build upon the clinical data implicating HIF2α as a negative prog-
nostic factor in human NSCLC and demonstrate in an autochtho-
nous cancer model that HIF2α can promote tumor progression in 
cancers other than renal cell carcinoma.
The majority of studies reinforce the notion that HIF is a positive 
regulator of tumor growth. For example, cell lines having reduced 
HIF transcriptional activity secondary to knockout of Hif1a or 
deficiency of Arnt grow more slowly under the skin of immuno-
compromised mice than wild-type controls (70–72). In genetically 
engineered mouse models, transgenic expression of Hif1a in basal 
keratinocytes facilitates the growth of HPV-16–induced cervical 
cancer, and conditional inactivation of Hif1a in a mouse mammary 
tumor model restrains the growth of polyoma middle T–induced 
breast tumors as well as pulmonary metastases (73, 74). However, 
other studies suggest that HIF may have a tumor suppressor role 
though induction of tumor cell apoptosis or cell-cycle arrest (75–78). 
Moreover, HIF can play starkly contrasting roles in tumor progres-
sion depending on the microenvironment in which the tumor cells 
are implanted, underscoring the importance of studying HIF in 
autochthonous tumor models (77). Our studies in the autochtho-
nous lung cancers of genetically engineered mice support the notion 
that HIF2α promotes solid tumor growth and aggressiveness.
In the setting of renal cell carcinoma, VHL loss and consequent 
upregulation of HIF is an early event (24). However, pVHL inacti-
vation or HIF activation alone does not appear to be sufficient for 
Figure 4
HIF2α-expressing tumors have increased vascularity and blood flow. (A) Quantification of microvessels per high-power field. Error bars indicate 1 
SEM. P < 0.001. (B) Immunohistochemistry for CD34 from lung tumors of LSL-Kras and LSL-Kras;LSL-HIF2 mice. Original magnification, ×100. 
(C) Quantification of percent vascularity of subcutaneously growing LSL-Kras and LSL-Kras;LSL-HIF2 tumors. Lines indicate mean (P = 0.028). 
(D and E) Representative pseudocolored Doppler ultrasound images of subcutaneously growing LSL-Kras and LSL-Kras;LSL-HIF2 tumors (D) 
and exponential decay curves of percent vascularity in relation to tumor volume (E). LSL-Kras: r2 = 0.87; LSL-Kras;LSL-HIF2: r2 = 0.21.
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the formation of tumors in humans or mice (16, 24, 47, 79–82). 
Similarly, in our studies, we did not see tumor formation or sig-
nificant histologic changes upon activation of only HIF2α in the 
lungs of LSL-HIF2 mice (data not shown). Furthermore, the tumor 
multiplicity of lungs from LSL-Kras and LSL-Kras;LSL-HIF2 mice 
did not differ significantly, suggesting that even in the presence 
of an oncogenic mutation such as mutant Kras, HIF2α does not 
initiate tumor formation.
In humans, non–small cell lung carcinomas can be subdivid-
ed into adeno-, squamous, and large cell carcinomas based on 
their histologic appearance. Kras-induced lung cancers in mice 
are uniformly well- to moderately differentiated adenocarcino-
mas. While concurrent loss of p53 or Pten appears to promote 
the development of higher-grade tumors, inactivation of these 
genes does not alter their histologic spectrum (44, 45). In con-
trast, Lkb1 inactivation within Kras-induced lung tumors results 
in an expanded histologic spectrum including adeno-, squamous, 
and large cell carcinomas (43). We noted that Lkb1-deficient 
squamous or mixed adenosquamous cell carcinomas expressed 
higher levels of Hif2a than Lkb1-deficient adenocarcinomas. We 
also noted that focal areas of HIF2α-producing tumors appeared 
to have squamous differentiation and stained positively for the 
squamous cell marker p63. Thus, while HIF2α appears to modu-
late the histologic spectrum of lung cancers, the low penetrance 
of squamous differentiation seen in our studies suggests that 
HIF2α expression alone is not sufficient to induce frank squa-
mous cell carcinomas. These data also suggest that some of the 
phenotypic and transcriptional effects of Lkb1 loss may also be 
secondary to increased expression of HIF2α.
The tumor microenvironment critically controls aspects of 
tumor growth and progression. In this regard, we present evidence 
that HIF2α can increase tumor vascularity and may also augment 
tumor blood flow, suggesting that the neoangiogenesis induced 
by HIF2α-producing tumors results in a functional vasculature, 
as has been seen previously in non-neoplastic settings (16, 47). 
While the assessment of vascularity was performed on the autoch-
thonous murine lung tumors, for technical reasons we had to 
assess the blood flow of HIF2α-producing lung tumors as tumor 
explants in which tumor cells are grown and examined under the 
skin of immunocompromised mice. Therefore, whether these 
studies adequately reflect the effects of HIF2α within autochtho-
nous lung tumors is uncertain.
While angiogenesis has been historically thought to be a local 
process, it has recently been appreciated that endothelium-derived 
endothelial cells (CECs) and their bone marrow–derived precursors 
(CEPs) can contribute to both physiologic and pathologic neoan-
giogenesis (83, 84). Interestingly, we detected increased numbers 
of both CECs and CEPs in the peripheral blood of mice harboring 
HIF2α-producing tumors relative to those expressing only mutant 
Kras. These results suggest that HIF2α production within tumors is 
able to mobilize CECs and CEPs from the mature endothelium or 
bone marrow. Although it is tempting to speculate that this results 
from an increased elaboration of proangiogenic factors in HIF2α-
producing tumors, the precise mechanism whereby HIF2α produc-
tion is signaled to the bone marrow and the importance of these 
cells to tumor neovascularization remains to be determined.
Finally, the histologic and gene expression changes seen in the 
HIF2dPA-expressing tumors suggest that HIF2α production on a 
backdrop of Kras activation results in more poorly differentiated 
tumors as well as induction of markers and mediators of EMT. 
Figure 5
Mice harboring HIF2α-producing tumors have increased numbers of 
CECs and CEPs. Quantification of CECs (A) and CEPs (B) in the periph-
eral blood by flow cytometry expressed as a percentage of viable mono-
nuclear cells. Error bars indicate 1 SEM. A: P = 0.027; B: P = 0.014.
Figure 6
HIF2α-producing tumors display markers of EMT. (A) Fold change in 
gene expression of markers or inducers of EMT in LSL-Kras;LSL-HIF2 
tumors relative to LSL-Kras tumors (Sip1, Snail, Zeb1, vimentin, and 
Twist). All P < 0.01. Error bars indicate 1 SEM. (B) Expression of vimentin 
by immunohistochemistry in LSL-Kras and LSL-Kras;LSL-HIF2 tumors.
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These findings in autochthonous tumors extend a body of in vitro 
and xenograft data previously demonstrating that either HIF1α 
or HIF2α can induce EMT (61–64, 85). Moreover, cross-species 
analysis of our HIF2α gene signature shows that HIF2α activa-
tion correlates with gene signatures of EMT in human lung cancer, 
supporting the notion that HIF2α initiates or is part of a genetic 
program resulting in EMT in human NSCLC.
HIF is predicted to transactivate a program of target genes that 
favor the progression of tumors. We have shown that HIF2α acti-
vation results in the promotion of tumor growth but not tumor 
Figure 7
Association between HIF2α activation and EMT gene signatures in human lung cancer. (A) Heat maps of relative enrichment scores of 
gene signatures of HIF2α, EMT, β-catenin, and TGF-β in human lung cancer cell lines and primary human NSCLC. Tumors or cell lines are 
represented in columns. Gene signatures are represented in rows. Red indicates high enrichment score. Green indicates low enrichment 
score. (B) Graphical representation of correlation between EMT, β-catenin, and TGF-β enrichment scores and HIF2α enrichment score. Dots 
represent a single cell line or tumor.
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initiation and that HIF2α’s effects on tumor size and invasiveness 
correlate with increased angiogenesis and expression of markers 
of EMT. Our data establish a causal link between HIF2α and the 
shortened survival of patients, describe a mechanism whereby 
HIF2α negatively impacts the overall survival of patients with 
NSCLC, and validate in autochthonous tumors that HIF2α is a 
promoter of tumor growth.
Methods
Mouse colony maintenance and Ad-Cre administration. The LSL-Kras mice were 
provided by Tyler Jacks’s laboratory (Massachusetts Institute of Technol-
ogy, Cambridge, Massachusetts, USA), were maintained on a mixed back-
ground, and have been described thoroughly (38). The LSL-HIF2 mice were 
maintained on a C57BL/6 background and have been described previ-
ously (16). All mice were housed and treated in accordance with protocols 
approved by the institutional care and use committees for animal research 
at the University of North Carolina and Dana-Farber Cancer Institute. 
Ad-Cre was purchased from the University of Iowa and administered at a 
dose of 2.5 × 105 PFU intranasally as previously described (38).
Histological studies. Mice were sacrificed, and the left lungs were 
removed for studies requiring fresh tissue. The remaining right lung 
and mediastinal structures were inflated with neutral buffered 10% for-
malin (Sigma-Aldrich) and fixed overnight at 4°C. Fixed tissues were 
paraffin embedded and stained with H&E by standard methods. For 
immunohistochemistry, 5-μm sections were deparaffinized in xylene 
and rehydrated sequentially in ethanol. For antibodies requiring anti-
gen retrieval, slides were boiled in 10 mM sodium citrate (pH 6.0) for 
30 minutes. Sections were stained with antibodies generated against 
CD34 (rat, 1:50; Abcam), Ki67 (Vector Laboratories), TUNEL (S7100; 
Chemicon, Millipore), vimentin (BD Biosciences — Pharmingen), and 
p63 (Cell Signaling Technology). Quantification of microvessel density 
was performed using the Weidner method as previously described (86). 
Tumor area quantification was performed by ImageJ (http://rsbweb.nih.
gov/ij/) measurements of tumor area and total lung area of 10 randomly 
chosen fields from the right apical lobe of each mouse. Tumor area was 
then expressed as percentage of total tumor area over total lung area. 
Tumor nodules were counted on one H&E slide representing a complete 
cross section of the lungs per animal. Nodules that contained (a) fibrotic 
stroma generation, (b) necrosis, (c) morphologically high-grade tumor 
cells, and (d) tumor cells showing squamous morphology were also iden-
tified and counted on these same slides.
Ultrasound and Doppler studies. Tumor cell lines derived from lung 
tumors were implanted into the subcutaneous space of 8-week-old nude 
mice and serially imaged using ultrasound and Doppler (Vevo 770 micro-
ultrasound; VisualSonics). Tumor volume was determined in smaller 
tumors by 3D reconstruction of ultrasound images using the Vevo 770 
software package. In larger tumors (exceeding the field of view of the 
probe), volume was determined by caliper measurement, using the for-
mula vol = 0.5 × L × W × W. Power Doppler mode imaging and percent 
vascularity was calculated using the Vevo 770 software package according 
to manufacturer’s protocols.
Circulating endothelial and progenitor cell measurements. EDTA-anticoagulat-
ed whole blood was obtained from mice via cardiac puncture. Red blood 
cells were lysed with ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM 
EDTA, pH 7.3). The cells were then incubated with FcR Blocking antibody 
(catalog 553142; BD Biosciences — Pharmingen) according to the man-
ufacturer’s instructions, followed by incubation with the following fluo-
rochrome-labeled monoclonal antibodies: anti-CD31 (PECAM-1)–FITC, 
anti-CD45–PE-Cy7, anti-CD117 (c-Kit)–APC, anti–VEGFR2 (Flk-1)–PE 
(all BD Biosciences — Pharmingen) or their appropriate isotype control 
antibodies. Dead cells were excluded by the use of 7-amino-actinomycin 
D (7AAD). CECs and CEPs, defined as CD31+CD45–CD117–VEGFR2+ 
and CD31+CD45–CD117+VEGFR2+, respectively, were quantified by flow 
cytometry (CyAn ADP flow cytometer; Beckman Coulter). All FACS data 
were analyzed by Flowjo software (Tree Star Inc.).
Microarray analysis. Mouse tumors were macrodissected, and total RNA 
was extracted. Labeled cDNA was synthesized using reverse transcription 
reactions carried out using 1 μg of mRNA. Briefly, tumor mRNA was 
labeled with Cy5-dUTP, while the pooled cell line reference RNA (Strata-
gene) was labeled with Cy3-dUTP using the Agilent Technologies Low 
RNA Input Linear Amplification Kit and hybridized overnight at 65°C 
to an Agilent 4 × 44K complete mouse genome 60mer oligonucleotide 
microarray. Arrays were washed and scanned using an Agilent Axon scan-
ner and uploaded to the University of North Carolina microarray data-
base, where the data are publicly available (https://genome.unc.edu/). 
Briefly, for analyses done using significance analysis of microarrays 
(SAM), data were excluded for genes with poor spot quality or with a 
mean intensity greater than twice the median background. Hierarchi-
cal clustering analyses were conducted using the program Cluster to do 
median-centered, average-linkage clustering, which was visualized using 
TreeView (http://jtreeview.sourceforge.net/). A total of 4,956 genes were 
selected from approximately 22,000 genes by filtering those with changes 
less than 0.5 SDs from the median gene expression. All data shown in the 
heat map figures are median centered.
GSEA analysis of murine lung tumors. GSEA was performed using GSEA 
2.0 downloaded from the Gene Set Enrichment Analysis website (http://
www.broad.mit.edu/gsea). The signal-to-noise metric and permutation 
of gene sets were used to rank the genes and calculate significance and 
FDR (P > 0.05, FDR > 0.05). Analysis was performed by collapsing probe 
sets to unique gene symbols and used to interrogate an established collec-
tion of curated gene sets provided by the Molecular Signatures Database 
(MSigDB, broad.mit.edu/gsea/msigdb) (87).
Gene signature analysis across human lung cancer datasets. Overlapping genes 
among the HIF2α, EMT, WNT/β-catenin, and TGF-β activation gene sig-
natures were first eliminated to remove bias during correlation compari-
sons. Full gene set lists are provided in Supplemental Table 1. Gene signa-
ture enrichment analysis and GSEA score assignment were performed as 
previously described (88) using Genomica software (genomica.weizmann.
ac.il). Briefly, normalized microarray data from the mouse tumors, the 
human lung cancer cell line dataset (downloaded from the NCBI GEO 
website [http://www.ncbi.nlm.nih.gov/geo/], data sets GSE4824 and 
GDS1688), and the human primary lung NSCLC compendium (down-
loaded from the National Cancer Institute caArray website [caarraydb.nci.
nih.gov], experiment ID 1015945236141280:1) (66) was first log2 trans-
formed, and then the mean expression level for each gene across all sam-
ples in a given dataset was calculated. These mean values were subtracted 
from all data points to obtain a matrix where negative values represent 
below-mean expression and positive values the opposite. Each sample 
was first scored for genes whose expression was at least 2-fold above or 
below the mean expression level. We then assessed the fraction of over- or 
underexpressed genes that belong to each tested gene set, calculating a 
P value for significant enrichment (P < 0.05). An FDR calculation was used 
to account for multiple hypothesis testing.
Pearson correlation. To quantify the association of the HIF2α signature 
with the EMT, TGF-β, and WNT/β-catenin signatures, we calculated the 
Pearson correlation between the scores across samples in the dataset. Scores 
were plotted in linear regression plots, and the probability of observing 
correlation was calculated by 1-sided t test. Pearson correlation and linear 
regression were calculated using GraphPad Prism 4.0 software. A P value 
less than 0.05 was considered significant.
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